Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections

This economic evaluation investigates the health outcomes and costs associated with use of monoclonal antibodies for treatment of SARS-CoV-2 in 14 scenarios stratified by age, vaccination status, and source of infection.

Detalles Bibliográficos
Autores principales: Park, Minah, Tan, Kelvin Bryan, Vasoo, Shawn, Dickens, Borame L., Lye, David, Cook, Alex R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984772/
https://www.ncbi.nlm.nih.gov/pubmed/35380647
http://dx.doi.org/10.1001/jamanetworkopen.2022.5750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984772/
https://www.ncbi.nlm.nih.gov/pubmed/35380647
http://dx.doi.org/10.1001/jamanetworkopen.2022.5750

Ejemplares similares